Epigenetic silencing of interleukin-10 by host-derived oxidized phospholipids supports a lethal inflammatory response to infections.
Summary
This mechanistic study shows that host-derived oxidized phospholipids formed during infection bind and inhibit AKT, enhancing the methionine cycle and EZH2 activity to epigenetically silence IL-10. The result is amplified inflammation without reducing pathogen burden, suggesting oxPL/EZH2 targeting could protect against lethal immunopathology.
Key Findings
- Host-derived oxidized phospholipids are generated after microbial encounter in mice and humans.
- oxPLs exacerbate inflammation without reducing pathogen burden.
- Mechanistically, oxPLs bind and inhibit AKT, enhance the methionine cycle and EZH2 activity, and epigenetically silence IL-10.
- Targeting oxPLs/EZH2 can prophylactically or therapeutically protect against deranged inflammation and immunopathology.
Clinical Implications
While preclinical, the work nominates oxPLs, EZH2, and upstream AKT signaling as therapeutic targets and potential biomarkers for hyperinflammatory respiratory failure. Translational studies in sepsis/ARDS should test oxPL-neutralizing or EZH2-modulating strategies.
Why It Matters
It uncovers a previously unappreciated lipid-epigenetic axis that controls anti-inflammatory signaling, offering actionable targets for hyperinflammatory conditions relevant to ARDS and sepsis.
Limitations
- Preclinical models limit direct clinical generalizability.
- Specific therapeutic interventions and safety in humans remain to be established.
Future Directions
Validate oxPL/EZH2/IL-10 axis biomarkers in sepsis/ARDS cohorts and test oxPL-neutralizing or EZH2-modulating agents in translational and early-phase clinical trials.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic evidence from animal models and human ex vivo analyses.
- Study Design
- OTHER